• About
  • Services
  • Clients
  • Client News
  • PCG Research
  • PCG Digital
  • Contact
  • follow:

  • 13 Sep

    OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

    NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced the development and in vitro concept data for two novel ADC therapeutic candidates leveraging the Company’s proprietary SiLinker™ technology. The Company has completed target engagement tests… Read More..

    Share this:
  • 9 Sep

    Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

    ASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today announced that its Chief Executive Officer, Michael Myers, and Chief Operating Officer, Denise Carter, have recently made significant purchases… Read More..

    Share this:
  • 6 Sep

    Aclarion Added to PRISM Emerging Medical Devices Index

    NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of market insights and company news, is excited to announce that Aclarion, Inc. (NASDAQ: ACON) has been added to the PRISM Emerging Medical Devices Index, which highlights companies at the forefront of innovation and market disruption in… Read More..

    Share this:
« Previous 1 … 55 56 57 58 59 … 244 Next »
  • Twitter feed is not available at the moment.
  • QUICK LINKS

    • About
    • Services
    • Clients
    • Client Media
    • PCG Media
    • PCG Research
    • Contact
    • Privacy Policy
    • Disclosures

    FOLLOW US

    Copyright © 2022 PCG Advisory.

    MENU logo
    • About
    • Services
    • Clients
    • Client News
    • PCG Research
    • PCG Digital
    • Contact